Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIO Trial: ART plus dual long-acting HIV-specific broadly neutralising antibodies vs ART plus placebo in primary HIV infection
2019-002129-31Phase 2Unknown
- Sponsor
- Imperial College London
- Start
- Sep 2019
- Modality
- Anti-infectious Disease mAbs → Neutralizing Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus infection (HIV) and Seroconversion Syndrome comparing ART + dual bNAbs (10-1074-LS + 3BNC117-LS) with ART + placebo (2 arms). Status: unknown.
02
Drugs
zinlirvimabTeropavimab
03
Conditions
human immunodeficiency virus infection (HIV)Seroconversion Syndrome
Beyond the preview
Go deeper on 2019-002129-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002129-31.